Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. Our products are used to purify pharmaceuticals during production using a technique called preparative chromatography.
We operate in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for NLAB Saga®, it can increase productivity and reduce costs for pharmaceutical manufacturers.
Our mission is to increase access to cost-effective drugs through its purification products, and thereby enable more patients around the world access to life-saving treatments for diabetes and obesity.
By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.
Nanologica has received another order for the company's silica-based purification media NLAB Saga® from a returning customer in China. This
The number of registered shares and votes in Nanologica AB has changed during the month of November following the registration
In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or
FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period
FINANSIELL SAMMANFATTNING • Nettoomsättningen för tredje kvartalet uppgick till 611 TSEK (342) och för niomånadersperioden till 7 822 TSEK (1
FINANSIELL SAMMANFATTNING • Nettoomsättningen för andra kvartalet uppgick till 2 174 TSEK (672) och för halvåret till 7 211 TSEK
2023 has been marked by geopolitical tensions and macroeconomic uncertainty. Like most others, Nanologica has been affected by this and we have had to prioritize our resources. On the other hand, we operate in a market segment that is virtually insensitive to economic cycles. We expect a commercial breakthrough in the near future and have a clear growth strategy for how we can capitalize on the strong market growth that exists in drugs for the treatment of diabetes and obesity.
Follow this link for more video presentations and CEO interviews.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
For further information, please contact:
Johanna Johansson
Director IR, Communications and Marketing
